|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
|
WO1990006952A1
(fr)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
|
DE69521880T2
(de)
*
|
1994-02-08 |
2002-01-03 |
Amgen Inc., Thousand Oaks |
Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
|
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
CA2204726A1
(en)
*
|
1994-11-09 |
1996-12-27 |
Robin E. Offord |
Functionalized polymers for site-specific attachment
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
|
DE69632062T2
(de)
|
1995-11-02 |
2004-11-18 |
Schering Corp. |
Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
|
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
|
ES2312179T3
(es)
|
1996-12-06 |
2009-02-16 |
Amgen Inc. |
Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
|
|
WO1998032466A1
(en)
*
|
1997-01-29 |
1998-07-30 |
Polymasc Pharmaceuticals Plc |
Pegylation process
|
|
JP4011124B2
(ja)
|
1997-06-06 |
2007-11-21 |
協和醗酵工業株式会社 |
化学修飾ポリペプチド
|
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
ES2297889T3
(es)
*
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
|
EE05214B1
(et)
*
|
1998-04-28 |
2009-10-15 |
Applied Research Systems ARS Holding N.V. |
Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
|
|
AU766597B2
(en)
*
|
1998-05-15 |
2003-10-16 |
Schering Corporation |
Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
|
|
NL1009601C2
(nl)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
|
|
EP1133563A2
(en)
*
|
1998-07-16 |
2001-09-19 |
Hyseq, Inc. |
Methods and molecules relating to cd39-like polypeptides
|
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
|
ATE498409T1
(de)
|
1998-08-06 |
2011-03-15 |
Mountain View Pharmaceuticals |
Peg-uricase konjugate und verwendung davon
|
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
BR9915548A
(pt)
*
|
1998-10-16 |
2001-08-14 |
Biogen Inc |
Proteìnas de fusão de interferon-beta e usos
|
|
HU229888B1
(en)
*
|
1998-10-16 |
2014-11-28 |
Biogen Idec Ma Inc Cambridge |
Polymer conjugates of interferon betha-1a and uses
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
MEP42108A
(en)
*
|
1998-10-23 |
2011-02-10 |
Kiren Amgen Inc |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1135493A2
(en)
*
|
1998-11-30 |
2001-09-26 |
Eli Lilly And Company |
Erythropoietic compounds
|
|
CA2359345A1
(en)
|
1999-01-14 |
2000-07-20 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
IL144361A0
(en)
*
|
1999-01-29 |
2002-05-23 |
Hoffmann La Roche |
Gcsf conjugates
|
|
SI1157037T1
(en)
*
|
1999-01-29 |
2003-12-31 |
F. Hoffmann-La Roche Ag |
Gcsf conjugates
|
|
WO2000051626A1
(en)
*
|
1999-03-01 |
2000-09-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Chemically modified g-csf preparations
|
|
US6485718B1
(en)
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US7160924B2
(en)
*
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
|
US7074878B1
(en)
*
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
|
KR100773323B1
(ko)
|
2000-01-10 |
2007-11-05 |
맥시겐 홀딩스 리미티드 |
지-씨에스에프 접합체
|
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
|
CA2739933A1
(en)
|
2000-02-11 |
2001-08-16 |
Bayer Healthcare Llc |
Factor vii or viia-like molecules
|
|
EP1129720B1
(en)
|
2000-02-29 |
2004-06-23 |
Pfizer Products Inc. |
Stabilized granulocyte colony stimulating factor
|
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
|
WO2001076639A2
(en)
*
|
2000-04-06 |
2001-10-18 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
|
AU2001257032A1
(en)
*
|
2000-04-14 |
2001-10-30 |
University Of South Carolina Research Foundation |
Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
|
|
DE60117781T2
(de)
|
2000-04-21 |
2006-11-23 |
Amgen Inc., Thousand Oaks |
Peptidderivate des apolipoproteins-a1/aii
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
MXPA03000310A
(es)
*
|
2000-07-12 |
2004-12-13 |
Gryphon Therapeutics Inc |
Quimiocinas sinteticas bioactivas, modificadas con polimeros y metodos para su elaboracion y uso.
|
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
KR20030057529A
(ko)
*
|
2000-09-08 |
2003-07-04 |
그리폰 테라퓨틱스, 인코포레이티드 |
합성 적혈구생성 자극 단백질
|
|
EP2295450B1
(en)
*
|
2000-09-29 |
2015-01-28 |
Merck Sharp & Dohme Corp. |
Pegylated interleukin-10
|
|
WO2002032957A1
(en)
*
|
2000-10-16 |
2002-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Peg-modified erythropoietin
|
|
CN1507357A
(zh)
*
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
提高生物活性分子传递的方法和组合物
|
|
WO2002036626A1
(en)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
Single-chain multimeric polypeptides
|
|
CN1321134C
(zh)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
一种生物活性蛋白质的非均一制品及其制备方法
|
|
EP2123293A3
(en)
*
|
2000-12-14 |
2010-09-08 |
Amylin Pharmaceuticals, Inc. |
Peptide YY and petide YY agonists for treatment of metabolic disorders
|
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
|
AU2002233230B2
(en)
*
|
2000-12-20 |
2007-02-01 |
F. Hoffmann-La Roche Ag |
Erythropoietin conjugates
|
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
|
CA2437287A1
(en)
*
|
2001-02-06 |
2002-10-03 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
|
|
EP1234583A1
(en)
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
JP2004535388A
(ja)
*
|
2001-04-30 |
2004-11-25 |
ターゲティッド ジェネティクス コーポレイション |
脂質含有薬物送達複合体およびそれらの生成方法
|
|
DK1385882T3
(da)
|
2001-05-11 |
2008-02-11 |
Amgen Inc |
Peptider og relaterede molekyler, der binder til TALL-1
|
|
CA2450985A1
(en)
*
|
2001-06-28 |
2003-01-09 |
Mountain View Pharmaceuticals, Inc. |
Polymer stabilized proteinases
|
|
EP1425304B9
(en)
*
|
2001-07-11 |
2010-09-08 |
Maxygen, Inc. |
G-csf conjugates
|
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
|
CN1738635A
(zh)
*
|
2001-10-05 |
2006-02-22 |
印特缪恩股份有限公司 |
用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
|
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
|
ES2654819T3
(es)
|
2001-10-18 |
2018-02-15 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opioides
|
|
CA2467557A1
(en)
*
|
2001-11-19 |
2003-05-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Agent which mobilizes multipotential stem cells from tissues to peripheral blood
|
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
WO2003044056A2
(en)
*
|
2001-11-20 |
2003-05-30 |
Pharmacia Corporation |
Chemically-modified human growth hormone conjugates
|
|
KR100480432B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체
|
|
AU2002346686A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
|
DE60323936D1
(de)
*
|
2002-01-14 |
2008-11-20 |
Gen Hospital Corp |
Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
|
|
PT3025726T
(pt)
*
|
2002-01-18 |
2020-01-09 |
Biogen Ma Inc |
Compostos do polímero polialquileno e utilizações dos mesmos
|
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
|
US20030191056A1
(en)
*
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
|
WO2003105763A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
|
EP1534269B1
(en)
*
|
2002-07-19 |
2013-10-30 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
|
JP2006508056A
(ja)
|
2002-08-28 |
2006-03-09 |
イミュネックス・コーポレーション |
心臓血管疾患を治療するための組成物および方法
|
|
KR20050093856A
(ko)
|
2002-09-09 |
2005-09-23 |
넥타르 테라퓨틱스 에이엘, 코포레이션 |
수용성 중합체 알카날
|
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US7538092B2
(en)
|
2002-10-08 |
2009-05-26 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
|
GEP20084487B
(en)
*
|
2002-12-26 |
2008-09-25 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
|
|
JP5207590B2
(ja)
*
|
2002-12-26 |
2013-06-12 |
マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド |
増強された生物学的能力を有するインターフェロン−βのポリマー結合体
|
|
CN1761680A
(zh)
|
2002-12-26 |
2006-04-19 |
武田药品工业株式会社 |
肿瘤迁移抑制素衍生物及其用途
|
|
EP1616003A4
(en)
|
2002-12-30 |
2007-06-20 |
Gryphon Therapeutics Inc |
WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
|
CA2516552A1
(en)
*
|
2003-02-26 |
2004-09-10 |
Intermune, Inc. |
Polyethylene glycol modified interferon compositions and methods of use thereof
|
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
|
NZ542094A
(en)
|
2003-03-14 |
2008-12-24 |
Neose Technologies Inc |
Branched polymer conjugates comprising a peptide and water-soluble polymer chains
|
|
CA2530725A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Biopolymed Inc. |
Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
|
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
|
US7587286B2
(en)
|
2003-03-31 |
2009-09-08 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
PL1615945T3
(pl)
|
2003-04-09 |
2012-03-30 |
Ratiopharm Gmbh |
Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
|
|
DK2599502T3
(en)
|
2003-04-11 |
2017-04-18 |
Antriabio Inc |
Process for Preparation of Site-Specific Protein Conjugates
|
|
EP2261244A3
(en)
|
2003-04-15 |
2011-02-23 |
Glaxosmithkline LLC |
Human il-18 substitution mutants and their conjugates
|
|
WO2004094592A2
(en)
|
2003-04-18 |
2004-11-04 |
Biogen Idec Ma Inc. |
Polymer-conjugated glycosylated neublastin
|
|
CA2525647A1
(en)
|
2003-05-16 |
2005-02-24 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
|
ATE460451T1
(de)
*
|
2003-07-22 |
2010-03-15 |
Nektar Therapeutics |
Verfahren zur herstellung von funktionalisierten polymeren aus polymeralkoholen
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
EP2133362B1
(en)
|
2003-07-25 |
2012-04-18 |
Amgen, Inc |
Methods relating to LDCAM and CRTAM
|
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
|
AU2004266969B2
(en)
*
|
2003-08-25 |
2010-02-25 |
Taniguchi, Tadatsugu |
Interferon-beta composite
|
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
|
CA2537336C
(en)
|
2003-09-17 |
2013-02-26 |
Nektar Therapeutics Al, Corporation |
Multi-arm polymer prodrugs
|
|
ES2361997T3
(es)
*
|
2003-09-22 |
2011-06-27 |
Boehringer Ingelheim International Gmbh |
Péptidos macrocíclicos activos contra el virus de la hepatitis c.
|
|
WO2005035727A2
(en)
*
|
2003-10-09 |
2005-04-21 |
Ambrx, Inc. |
Polymer derivatives
|
|
CN1867581B
(zh)
|
2003-10-10 |
2012-02-01 |
诺沃挪第克公司 |
Il-21衍生物
|
|
EP1675871A2
(en)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
|
WO2005037214A2
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
|
EP1725572B1
(de)
|
2003-11-05 |
2017-05-31 |
AGCT GmbH |
Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
WO2005053730A1
(ja)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
末期心不全治療剤
|
|
WO2005067963A1
(en)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
NZ548123A
(en)
|
2004-01-08 |
2010-05-28 |
Novo Nordisk As |
O-linked glycosylation of peptides
|
|
ATE495185T1
(de)
*
|
2004-01-21 |
2011-01-15 |
Boehringer Ingelheim Int |
Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
|
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
|
US8076288B2
(en)
*
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US8603969B2
(en)
*
|
2004-02-11 |
2013-12-10 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
NZ579621A
(en)
|
2004-02-11 |
2011-03-31 |
Amylin Pharmaceuticals Inc |
Hybrid polypeptides with selectable properties
|
|
US20090214472A1
(en)
*
|
2004-03-01 |
2009-08-27 |
Enzon Pharmaceuticals Inc. |
Interferon-beta polymer conjugates
|
|
AU2005229001A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen Inc. |
Chemically modified protein compositions and methods
|
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
|
CN101115769A
(zh)
|
2004-05-19 |
2008-01-30 |
马克西根公司 |
干扰素-α多肽和偶联物
|
|
WO2005123113A2
(en)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Interferon compositions and methods of use thereof
|
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
|
CA2571420A1
(en)
|
2004-06-25 |
2006-01-05 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
|
WO2006004959A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Pegylated interferon alpha-1b
|
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
|
US20080300173A1
(en)
*
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
|
CA2577690C
(en)
|
2004-08-19 |
2013-08-06 |
Biogen Idec Ma Inc. |
Refolding transforming growth factor beta family proteins
|
|
DK1786454T3
(da)
|
2004-08-19 |
2010-09-06 |
Biogen Idec Inc |
Neublastinvarianter
|
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
|
CA2581423A1
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
AU2005306894B2
(en)
|
2004-11-05 |
2011-11-24 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
|
EP2360180A3
(en)
|
2004-12-13 |
2012-02-08 |
Amylin Pharmaceuticals Inc. |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
EP1674113A1
(en)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
|
|
EP1836298B1
(en)
*
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
|
EP2399893B1
(en)
|
2004-12-22 |
2018-08-15 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
EP1836316A4
(en)
|
2004-12-22 |
2009-07-22 |
Ambrx Inc |
PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
|
|
CN103520735B
(zh)
*
|
2004-12-22 |
2015-11-25 |
Ambrx公司 |
包含非天然编码的氨基酸的人生长激素配方
|
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
BRPI0606934A2
(pt)
|
2005-01-25 |
2017-07-11 |
Cell Therapeutics Inc |
Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
|
|
JPWO2006080171A1
(ja)
*
|
2005-01-31 |
2008-06-19 |
株式会社 エフェクター細胞研究所 |
免疫増強剤
|
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
|
WO2007022123A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
KR20070115947A
(ko)
|
2005-02-11 |
2007-12-06 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
|
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
|
CN102343084A
(zh)
|
2005-03-31 |
2012-02-08 |
安米林药品公司 |
用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
|
|
EP1868652A2
(en)
|
2005-04-05 |
2007-12-26 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Method for shielding functional sites or epitopes on proteins
|
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
SG161247A1
(en)
|
2005-04-11 |
2010-05-27 |
Savient Pharmaceuticals Inc |
Variant forms of urate oxidase and use thereof
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
EP1888633A4
(en)
|
2005-05-18 |
2010-01-27 |
Maxygen Inc |
UNFOLDED INTERFERON ALPHA POLYPEPTIDE
|
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
KR20080027291A
(ko)
*
|
2005-06-01 |
2008-03-26 |
맥시겐 홀딩스 엘티디 |
피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
|
|
TW200722521A
(en)
*
|
2005-06-01 |
2007-06-16 |
Alza Corp |
Novel bioconjugation reactions for acylating polyethylene glycol reagents
|
|
WO2007009208A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
|
AU2006255122B2
(en)
*
|
2005-06-03 |
2010-10-21 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
|
WO2006135930A2
(en)
*
|
2005-06-13 |
2006-12-21 |
Nastech Pharmaceutical Company Inc. |
Transmucosal delivery of peptide derivatives
|
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
|
AU2006259348B2
(en)
|
2005-06-17 |
2010-07-22 |
Novartis Ag |
Use of sanglifehrin in HCV
|
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
|
CA2612901A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Pepgen Corporation |
Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
|
|
US8568705B2
(en)
*
|
2005-07-18 |
2013-10-29 |
Nektar Therapeutics |
Method for preparing branched functionalized polymers using branched polyol cores
|
|
KR100735784B1
(ko)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
|
MX2008001166A
(es)
|
2005-07-25 |
2008-03-18 |
Intermune Inc |
Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
|
|
WO2007015591A1
(en)
*
|
2005-08-02 |
2007-02-08 |
Cheil Industries Inc. |
Epoxy resin composition for packaging semiconductor device
|
|
US20070092482A1
(en)
*
|
2005-08-04 |
2007-04-26 |
Bossard Mary J |
Conjugates of a G-CSF moiety and a polymer
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
AU2005335491B2
(en)
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
PL1971362T3
(pl)
|
2005-08-19 |
2015-05-29 |
Amylin Pharmaceuticals Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
|
AU2006301966A1
(en)
|
2005-10-11 |
2007-04-19 |
Array Biopharma, Inc. |
Compounds and methods for inhibiting hepatitis C viral replication
|
|
WO2007047303A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Pegylated glutenase polypeptides
|
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
|
AU2006304856A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Synageva Biopharma Corp. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
CN101400646A
(zh)
*
|
2005-11-08 |
2009-04-01 |
Ambrx公司 |
用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
|
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
|
DK2339014T3
(en)
*
|
2005-11-16 |
2015-07-20 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
|
WO2007070659A2
(en)
*
|
2005-12-14 |
2007-06-21 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
|
ES2530526T3
(es)
|
2005-12-30 |
2015-03-03 |
Zensun Shanghai Science And Technology Ltd |
Liberación extendida de neurregulina para mejorar la función cardíaca
|
|
AU2007205545B9
(en)
|
2006-01-12 |
2012-10-18 |
Hokusan Co. Ltd. |
Oral composition containing interferon-alpha
|
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
|
EP1991577A2
(en)
|
2006-01-31 |
2008-11-19 |
Parkinson, John F. |
Modulation of mdl-1 activity for treatment of inflammatory disease
|
|
US8309680B2
(en)
|
2006-02-21 |
2012-11-13 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
|
EP2007789B1
(en)
|
2006-04-11 |
2015-05-20 |
Novartis AG |
Spirocyclic HCV/HIV inhibitors and their uses
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
EP2029160A2
(en)
*
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
US7851438B2
(en)
|
2006-05-19 |
2010-12-14 |
GlycoFi, Incorporated |
Erythropoietin compositions
|
|
KR20090013816A
(ko)
|
2006-05-24 |
2009-02-05 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
|
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
|
US8840882B2
(en)
*
|
2006-06-23 |
2014-09-23 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
|
US20080096900A1
(en)
|
2006-06-26 |
2008-04-24 |
Amgen Inc. |
Methods for treating atherosclerosis
|
|
WO2008010991A2
(en)
|
2006-07-17 |
2008-01-24 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
|
EP2049144B8
(en)
*
|
2006-07-21 |
2015-02-18 |
ratiopharm GmbH |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
US8299015B2
(en)
|
2006-07-25 |
2012-10-30 |
Lipoxen Technologies Limited |
Derivatisation of granulocyte colony-stimulating factor
|
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
|
PL2054074T3
(pl)
*
|
2006-08-04 |
2015-03-31 |
Prolong Pharmaceuticals Llc |
Zmodyfikowana erytropoetyna
|
|
ITMI20061624A1
(it)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
JP4958975B2
(ja)
*
|
2006-08-31 |
2012-06-20 |
エフ．ホフマン−ラ ロシュ アーゲー |
インスリン様増殖因子ｉの製造方法
|
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
|
CN106008699A
(zh)
*
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
|
EP2064333B1
(en)
*
|
2006-09-08 |
2014-02-26 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
|
JP5399906B2
(ja)
*
|
2006-09-08 |
2014-01-29 |
アンブルックス，インコーポレイテッド |
脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
|
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
EP2066336B1
(en)
|
2006-09-28 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Use of pegylated il-10 to treat cancer
|
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
|
|
ES2655734T3
(es)
*
|
2006-10-04 |
2018-02-21 |
Novo Nordisk A/S |
Glicopéptidos y azúcares pegilados unidos a glicerol
|
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
|
PE20081140A1
(es)
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
|
JO3048B1
(ar)
|
2006-10-25 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مشتقات متاستين واستخدامها
|
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
|
MX2009005466A
(es)
|
2006-11-22 |
2009-08-17 |
Adnexus A Bristol Myers Sqibb |
Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
|
|
WO2008073300A2
(en)
|
2006-12-08 |
2008-06-19 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
|
EP2111228B1
(en)
|
2007-02-02 |
2011-07-20 |
Bristol-Myers Squibb Company |
10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
|
|
CN101245109B
(zh)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
|
|
CN107501407B
(zh)
|
2007-03-30 |
2022-03-18 |
Ambrx公司 |
经修饰fgf-21多肽和其用途
|
|
HRP20130382T1
(hr)
|
2007-04-03 |
2013-05-31 |
Biogenerix Ag |
Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
|
|
JP2008266219A
(ja)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
リジン及びシステイン残基を含まないタンパク質
|
|
EP2142205B1
(en)
|
2007-05-01 |
2014-04-02 |
Biogen Idec MA Inc. |
Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
|
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
|
EP2162540A2
(en)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
|
WO2008151258A2
(en)
*
|
2007-06-04 |
2008-12-11 |
Neose Technologies, Inc. |
O-linked glycosylation using n-acetylglucosaminyl transferases
|
|
CA2690611C
(en)
|
2007-06-12 |
2015-12-08 |
Novo Nordisk A/S |
Improved process for the production of nucleotide sugars
|
|
US20110159523A1
(en)
*
|
2007-06-27 |
2011-06-30 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
|
HRP20140315T1
(hr)
|
2007-07-26 |
2014-05-09 |
Amgen Inc. |
Modificirani enzimi lecitin-kolesterol aciltransferaze
|
|
CN101352573B
(zh)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
|
|
US20090324609A1
(en)
|
2007-08-09 |
2009-12-31 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
|
MX2010002448A
(es)
|
2007-08-27 |
2010-10-04 |
Biogenerix Ag |
Formulacion liquida del g-csf conjugado.
|
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
|
WO2009048909A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
US8440787B2
(en)
*
|
2007-10-23 |
2013-05-14 |
Nektar Therapeutics |
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
|
|
MX2010005317A
(es)
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
|
CA2707979A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Biovectra Inc. |
Polypeptides modified by protein trans-splicing technology
|
|
EP2416157B1
(en)
|
2007-12-27 |
2014-07-30 |
Baxter International Inc. |
Method and compositions for specifically detecting physiologically acceptable polymer molecules
|
|
US20100316702A1
(en)
*
|
2008-01-08 |
2010-12-16 |
The Regents Of The University Of California |
Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis
|
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
CA2711590C
(en)
|
2008-01-18 |
2021-03-23 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
|
MX344166B
(es)
|
2008-02-08 |
2016-12-07 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
|
JP5225393B2
(ja)
*
|
2008-02-18 |
2013-07-03 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
水溶性高分子修飾ｇ−ｃｓｆ複合体
|
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US20110045510A1
(en)
*
|
2008-04-03 |
2011-02-24 |
Kurt Lang |
Pegylated insulin-like-growth-factor assay
|
|
US9840546B2
(en)
*
|
2008-04-03 |
2017-12-12 |
Biosteed Gene Expression Tech. Co., Ltd. |
Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
|
|
KR20130116386A
(ko)
|
2008-04-14 |
2013-10-23 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
|
US8034770B2
(en)
|
2008-06-04 |
2011-10-11 |
Amgen Inc. |
FGF21 polypeptides comprising two or more mutations
|
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
CN102159230A
(zh)
|
2008-07-23 |
2011-08-17 |
Ambrx公司 |
经修饰的牛g-csf多肽和其用途
|
|
LT2314609T
(lt)
*
|
2008-07-30 |
2017-04-10 |
Takeda Pharmaceutical Company Limited |
Metastino darinys ir jo panaudojimas
|
|
AR072850A1
(es)
*
|
2008-07-31 |
2010-09-22 |
Pharmaessentia Corp |
Conjugados peptido-polimero
|
|
AU2009282413B2
(en)
|
2008-08-11 |
2014-07-17 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
|
JP5766118B2
(ja)
|
2008-09-11 |
2015-08-19 |
ウェルズ ファーゴ バンク ナショナル アソシエイション |
ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
|
|
AU2009296267B2
(en)
*
|
2008-09-26 |
2013-10-31 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
|
BR122012024318A2
(pt)
|
2008-09-26 |
2019-07-30 |
Ambrx, Inc. |
Polipeptídeos modificados de eritropoetina animal e seus usos
|
|
BRPI0920743A2
(pt)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
ribonucleases terapeuticas
|
|
CA2739615C
(en)
|
2008-10-10 |
2017-12-05 |
Amgen Inc. |
Fgf21 mutants comprising polyethylene glycol and uses thereof
|
|
DK2349341T3
(da)
|
2008-10-15 |
2014-01-06 |
Baxter Int |
Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
|
|
US20100099616A1
(en)
|
2008-10-17 |
2010-04-22 |
Baxter International Inc. |
Modified blood factors comprising a low degree of water soluble polymer
|
|
CA2741209C
(en)
|
2008-10-20 |
2016-12-20 |
Usv Limited |
An improved process for pegylation of proteins
|
|
PL2431741T3
(pl)
|
2008-10-21 |
2014-01-31 |
Baxalta Inc |
Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
|
|
AU2009308909A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Amgen Inc. |
Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
|
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
EA022752B1
(ru)
|
2008-12-09 |
2016-02-29 |
Галозим, Инк. |
Длинные растворимые полипептиды рн20 и их использование
|
|
JP5568091B2
(ja)
*
|
2008-12-11 |
2014-08-06 |
バクスター・インターナショナル・インコーポレイテッド |
近赤外分光法を用いた生理学的に許容されるポリマー分子の検出
|
|
ES2655364T3
(es)
|
2008-12-17 |
2018-02-19 |
Merck Sharp & Dohme Corp. |
Producción de IL-10 mono- y dipegilada y sus usos
|
|
JP5866117B2
(ja)
*
|
2009-04-06 |
2016-02-17 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
分子を送達するための方法および材料
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
WO2010129503A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
|
WO2010129600A2
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
|
PT2432489T
(pt)
|
2009-05-20 |
2016-12-07 |
Biomarin Pharm Inc |
Variantes do péptido natriurético de tipo c
|
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
|
WO2010148413A2
(en)
|
2009-06-19 |
2010-12-23 |
Medimmune, Llc |
Protease variants
|
|
US9377454B2
(en)
|
2009-06-25 |
2016-06-28 |
Crealta Pharmaceuticals Llc |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
|
HUE028832T2
(en)
|
2009-09-17 |
2017-01-30 |
Baxalta Inc |
Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
|
|
EP2480888B1
(en)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening methods
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
EP2480578A4
(en)
*
|
2009-09-25 |
2013-04-17 |
Vybion Inc |
MODIFICATION OF POLYPEPTIDE
|
|
EP2494073B1
(de)
|
2009-10-26 |
2017-11-29 |
AGCT GmbH |
Konjugate von nukleotiden und methoden zu deren anwendung
|
|
CN102695723A
(zh)
|
2009-10-30 |
2012-09-26 |
中枢神经系统治疗学公司 |
改进的神经营养因子分子
|
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
|
EP2504021A4
(en)
|
2009-11-23 |
2013-05-15 |
Amylin Pharmaceuticals Llc |
Polypeptide conjugate
|
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
BR112012015597A2
(pt)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
peptídeos de somatotropina suínos modificados e seus usos
|
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
|
EP2536753B1
(en)
|
2010-02-16 |
2017-12-20 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
|
EP2542574B1
(en)
*
|
2010-03-04 |
2017-08-09 |
Pfenex Inc. |
Method for producing soluble recombinant interferon protein without denaturing
|
|
AU2011235210B2
(en)
|
2010-04-01 |
2015-07-16 |
Pfenex Inc. |
Methods for G-CSF production in a Pseudomonas host cell
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
CA2797093C
(en)
|
2010-04-26 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
|
EP2563381B1
(en)
|
2010-04-27 |
2017-08-09 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
|
CN103097524B
(zh)
|
2010-04-28 |
2016-08-03 |
Atyr医药公司 |
与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
|
EP2563383B1
(en)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
|
CN102234310B
(zh)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
一种聚乙二醇修饰蛋白的分离纯化方法
|
|
AU2011248227B2
(en)
|
2010-05-03 |
2016-12-01 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
|
|
CN103096925A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
ES2668207T3
(es)
|
2010-05-03 |
2018-05-17 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
|
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ， インコーポレイテッド |
ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
|
EP2568996B1
(en)
|
2010-05-14 |
2017-10-04 |
aTyr Pharma, Inc. |
Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
|
US9034598B2
(en)
|
2010-05-17 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
|
KR20130115086A
(ko)
|
2010-05-17 |
2013-10-21 |
세빅스 인코포레이티드 |
페길화된 c-펩티드
|
|
JP6023703B2
(ja)
|
2010-05-26 |
2016-11-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
|
|
CN103096913B
(zh)
|
2010-05-27 |
2017-07-18 |
Atyr 医药公司 |
与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
CA2800281C
(en)
|
2010-06-01 |
2021-01-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
|
JP2013529627A
(ja)
|
2010-06-24 |
2013-07-22 |
パンメド リミテッド |
ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
|
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
|
JP2013532176A
(ja)
|
2010-07-15 |
2013-08-15 |
ノヴォ ノルディスク アー／エス |
安定化させた第ｖｉｉｉ因子バリアント
|
|
WO2012012300A2
(en)
|
2010-07-20 |
2012-01-26 |
Halozyme, Inc. |
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
|
|
AR082319A1
(es)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2446173C1
(ru)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
EA030886B1
(ru)
|
2010-08-17 |
2018-10-31 |
Амбркс, Инк. |
Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
|
|
CN103108650A
(zh)
|
2010-08-25 |
2013-05-15 |
Atyr医药公司 |
与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
JP6042335B2
(ja)
|
2010-09-15 |
2016-12-14 |
ノヴォ ノルディスク アー／エス |
細胞取込みが低下した第ｖｉｉｉ因子変異体
|
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
|
PT2621515T
(pt)
|
2010-09-28 |
2017-07-12 |
Aegerion Pharmaceuticals Inc |
Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
|
|
CN103179974A
(zh)
|
2010-10-05 |
2013-06-26 |
诺华有限公司 |
丙型肝炎病毒感染的新疗法
|
|
JP5909495B2
(ja)
|
2010-10-08 |
2016-04-26 |
ノバルティス アーゲー |
スルファミドｎｓ３阻害剤のビタミンｅ製剤
|
|
CN102453089B
(zh)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
|
CN103933577B
(zh)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
JP6033229B2
(ja)
|
2010-11-24 |
2016-11-30 |
レクシコン ファーマシューティカルズ インコーポレイテッド |
Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
|
|
CA2818067A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
|
CN102485742A
(zh)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
|
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
|
EP2654795B1
(en)
|
2010-12-21 |
2018-03-07 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
|
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
PH12013501865A1
(en)
|
2011-03-16 |
2014-01-06 |
Amgen Inc |
Potent and selective inhibitors of nav1.3 and nav1.7
|
|
AU2012236889A1
(en)
*
|
2011-03-25 |
2013-05-09 |
The Trustees Of Columbia University In The City Of New York |
Pegylated human HDL particle and process for production thereof
|
|
AU2012233644A1
(en)
|
2011-03-31 |
2013-09-12 |
Novartis Ag |
Alisporivir to treat Hepatitis C virus infection
|
|
AU2012237295A1
(en)
|
2011-04-01 |
2013-09-19 |
Novartis Ag |
Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
|
|
CN103648516A
(zh)
|
2011-04-13 |
2014-03-19 |
诺华股份有限公司 |
使用阿拉泊韦治疗丙型肝炎病毒感染
|
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
|
CA2839512C
(en)
|
2011-06-17 |
2018-01-02 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
|
RU2654231C2
(ru)
|
2011-06-28 |
2018-05-17 |
Алтернатив Инновейтив Текнолоджиз, Ллц |
Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты)
|
|
RU2014103288A
(ru)
|
2011-07-01 |
2015-08-10 |
Байер Интеллектчуал Проперти Гмбх |
Слитые полипептиды релаксина и их применение
|
|
CN103747807B
(zh)
|
2011-07-05 |
2016-12-07 |
比奥阿赛斯技术有限公司 |
P97‑抗体缀合物和使用方法
|
|
CN103957926B
(zh)
|
2011-07-08 |
2018-07-03 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
|
CN102952067A
(zh)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
|
|
MX2014002260A
(es)
|
2011-08-31 |
2014-08-18 |
Amgen Inc |
Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
|
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
RU2014116988A
(ru)
|
2011-09-27 |
2015-11-10 |
Новартис Аг |
Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
|
|
RU2014114849A
(ru)
|
2011-10-14 |
2015-11-20 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
|
|
JP6162707B2
(ja)
|
2011-10-24 |
2017-07-12 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
|
|
WO2013063277A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
|
US8962553B2
(en)
|
2011-11-17 |
2015-02-24 |
Cebix Ab |
Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
|
|
RU2685867C2
(ru)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
|
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
|
CA2861402C
(en)
|
2012-01-30 |
2021-10-12 |
Guy Casy |
Stabilized aqueous antibody compositions
|
|
EP2814514B1
(en)
|
2012-02-16 |
2017-09-13 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
MX2014010209A
(es)
|
2012-02-29 |
2014-11-21 |
Toray Industries |
Agente inhibidor para acumulacion de fluido de la cavidad corporal.
|
|
PT2822575T
(pt)
|
2012-03-03 |
2020-07-02 |
Immungene Inc |
Moléculas de fusão anticorpos-mutante de interferão modificadas
|
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
|
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
|
CN108686203A
(zh)
|
2012-04-04 |
2018-10-23 |
哈洛齐梅公司 |
使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2013192596A2
(en)
|
2012-06-22 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind ccr2
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
CA3140358A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
EP2890402B1
(en)
|
2012-08-31 |
2019-04-17 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
AU2013341711A1
(en)
|
2012-11-12 |
2015-05-21 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
|
WO2014078733A1
(en)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Pictet-spengler ligation for protein chemical modification
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
|
US20160067347A1
(en)
|
2012-12-20 |
2016-03-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
|
CN103908660B
(zh)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
|
|
EP2951206A2
(en)
|
2013-02-01 |
2015-12-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
|
CN103113466B
(zh)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
聚乙二醇修饰的重组人干扰素β-1b及制备方法
|
|
WO2014165277A2
(en)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
POTENT AND SELECTIVE INHIBITORS OF Nav1.7
|
|
AU2014243816B2
(en)
|
2013-03-13 |
2019-01-31 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
RU2535002C2
(ru)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
|
|
MX2015014438A
(es)
|
2013-04-18 |
2016-05-18 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
EP3010527B1
(en)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
US20160271265A1
(en)
|
2013-10-02 |
2016-09-22 |
Novartis Ag |
Insulin-like growth factor mimetics for use in therapy
|
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
|
CN120242030A
(zh)
|
2013-11-11 |
2025-07-04 |
阿尔莫生物科技股份有限公司 |
将白细胞介素-10用于治疗疾病和病症的方法
|
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
|
CN115504924A
(zh)
|
2013-11-27 |
2022-12-23 |
雷德伍德生物科技股份有限公司 |
肼基-吡咯并化合物及用于生成缀合物的方法
|
|
UY35874A
(es)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
Un proceso para la preparación de una composición de proteínas pegiladas
|
|
WO2015130963A2
(en)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
WO2015191781A2
(en)
|
2014-06-10 |
2015-12-17 |
Amgen Inc. |
Apelin polypeptides
|
|
EP3973994A1
(en)
|
2014-06-12 |
2022-03-30 |
RA Pharmaceuticals, Inc. |
Modulation of complement activity
|
|
EA201790437A1
(ru)
|
2014-08-22 |
2017-08-31 |
Сорренто Терапьютикс, Инк. |
Антигенсвязывающие белки, связывающиеся с cxcr3
|
|
PT3186281T
(pt)
|
2014-08-28 |
2019-07-10 |
Halozyme Inc |
Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
|
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
WO2016060996A2
(en)
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
CN114805532A
(zh)
|
2014-10-24 |
2022-07-29 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
|
JP6820841B2
(ja)
|
2014-11-06 |
2021-01-27 |
ファーマエッセンティア コーポレイション |
ペグ化インターフェロンのための投薬計画
|
|
US20160151511A1
(en)
*
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
|
CN104491843B
(zh)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG‑CSF活性药物组合物
|
|
US9937222B2
(en)
|
2015-01-28 |
2018-04-10 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
TWI849231B
(zh)
*
|
2015-03-03 |
2024-07-21 |
香港商南沙生物科技（香港）有限公司 |
聚乙二醇化介白素-11之組合物及方法
|
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
JP6525171B2
(ja)
|
2015-04-13 |
2019-06-05 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
|
CN115919996A
(zh)
|
2015-05-01 |
2023-04-07 |
雅利斯塔制药公司 |
用于治疗眼科疾病的脂联素拟肽
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
CA2994841A1
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
|
KR20180038553A
(ko)
|
2015-08-25 |
2018-04-16 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
NZ740534A
(en)
*
|
2015-09-18 |
2019-07-26 |
Univ Miyazaki |
Long-acting adrenomedullin derivative
|
|
US20180280474A1
(en)
|
2015-10-01 |
2018-10-04 |
Amgen Inc. |
Treatment of bile acid disorders
|
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
|
EP3373937B1
(en)
|
2015-11-09 |
2021-12-22 |
R.P. Scherer Technologies, LLC |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
HUE057083T2
(hu)
|
2015-12-08 |
2022-04-28 |
Biomarin Pharm Inc |
C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
|
|
RU2733720C2
(ru)
|
2015-12-16 |
2020-10-06 |
Ра Фармасьютикалз, Инк. |
Модуляторы активности комплемента
|
|
ES3064816T3
(en)
|
2016-01-08 |
2026-04-29 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with reduced side-effects
|
|
WO2017132562A1
(en)
|
2016-01-29 |
2017-08-03 |
Heyue Zhou |
Antigen binding proteins that bind pd-l1
|
|
AU2017250778B2
(en)
|
2016-04-15 |
2021-09-23 |
Beckman Coulter, Inc. |
Photoactive macromolecules and uses thereof
|
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
|
CN116637177A
(zh)
|
2016-11-11 |
2023-08-25 |
好利恩治疗美国公司 |
泼尼松和尿酸酶分子的组合疗法及其用途
|
|
KR20190093196A
(ko)
|
2016-12-07 |
2019-08-08 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절인자
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
JP7097885B2
(ja)
|
2016-12-12 |
2022-07-08 |
ベクトン・ディキンソン・アンド・カンパニー |
水溶性ポリマー色素
|
|
PE20191716A1
(es)
|
2017-02-08 |
2019-12-05 |
Bristol Myers Squibb Co |
Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
|
|
CA3177086A1
(en)
|
2017-06-22 |
2018-12-27 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
KR102020995B1
(ko)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
|
|
CN119286279A
(zh)
|
2017-12-26 |
2025-01-10 |
贝克顿·迪金森公司 |
深紫外线可激发的水溶剂化聚合物染料
|
|
WO2019130344A1
(en)
|
2017-12-27 |
2019-07-04 |
Council Of Scientific And Industrial Research |
A polypeptide exhibiting granulocyte-colony stimulating factor activity
|
|
CN112135837A
(zh)
*
|
2018-03-14 |
2020-12-25 |
勇·巴 |
聚乙二醇化抗冻蛋白及其制备和使用方法
|
|
EP3775052B1
(en)
|
2018-03-30 |
2024-06-05 |
Becton, Dickinson and Company |
Water-soluble polymeric dyes having pendant chromophores
|
|
AU2019260418B2
(en)
|
2018-04-24 |
2024-12-12 |
Amgen Inc. |
Method for making injectable pharmaceutical compositions
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
|
EP3813867A1
(en)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Treatment of lymmphatic metastases
|
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス，インコーポレイテッド |
インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
|
|
CA3123872A1
(en)
|
2018-12-28 |
2020-07-02 |
Catalyst Biosciences, Inc. |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
WO2020160322A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
|
|
WO2020160325A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
CA3128081A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
JP7281140B2
(ja)
|
2019-04-15 |
2023-05-25 |
日油株式会社 |
生体関連物質とブロックポリマーとの結合体、および前記結合体を得るためのブロックポリマー誘導体
|
|
JP2022535411A
(ja)
|
2019-06-04 |
2022-08-08 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体阻害剤による炎症性疾患治療
|
|
EP4117732A1
(en)
|
2020-03-11 |
2023-01-18 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
|
WO2021188869A2
(en)
|
2020-03-20 |
2021-09-23 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス，インコーポレイテッド |
抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
|
|
US11602598B1
(en)
*
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
|
CN112710826A
(zh)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
一种提高试剂稳定性的包被和封闭方法
|
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
CN113214328B
(zh)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
一种双水相体系以及基于双水相体系的单糖分离方法
|
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
|
US20250383357A1
(en)
|
2022-07-01 |
2025-12-18 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
|
EP4680677A1
(en)
|
2023-03-17 |
2026-01-21 |
Beckman Coulter, Inc. |
Benzothienopyrrole cyanine dyes
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|
|
CN121866309A
(zh)
|
2023-09-21 |
2026-04-14 |
贝克曼库尔特有限公司 |
用于流式细胞术的二氢菲（dhp）桥接染料
|
|
WO2025227129A2
(en)
|
2024-04-25 |
2025-10-30 |
Starrock Pharma Llc |
Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
|
|
US20250341516A1
(en)
|
2024-05-01 |
2025-11-06 |
BioLegend, Inc. |
Compositions for use with multiple fluorophores and methods of using
|
|
WO2026043823A2
(en)
|
2024-08-19 |
2026-02-26 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
|